While nasal administration of albumin-fused ACE2 is motivated by delivery at the primary site of infection, combined with the ability to engage FcRn for half-life extension and transmucosal transport to local tissues and blood (76), bioencapsulation may not be required to withstand the acidic and enzymatic conditions within the gastrointestinal tract. The gene discussed is ALB; the disease is infection.